Literature DB >> 373792

A randomized double-blind trial of two low dose combined oral contraceptives.

W Bounds, M Vessey, P Wiggins.   

Abstract

Fifty-five women using Loestrin-20 (20 microgram ethinyl oestradiol and 1 mg norethisterone acetate) as an oral contraceptive have been compared with a like number using Microgynon-30 (30 microgram ethinyl oestradiol and 150 microgram levonorgestrel) in a randomized, double-blind trial. Despite the small sample size, the main finding in the trial is clear-cut; Loestrin-20 provides poor cycle control and is thus less acceptable as an oral contraceptive than Microgynon-30. Although there is also a suggestion that Loestrin-20 may be less effective than Microgynon-30, the difference in the accidental pregnancy rates is not statistically significant.

Entities:  

Keywords:  Amenorrhea; Bleeding; Comparative Studies; Contraception; Contraceptive Effectiveness; Contraceptive Methods--side effects; Developed Countries; Diseases; England; Europe; Family Planning; Menstruation Disorders; Metrorrhagia; Northern Europe; Oral Contraceptives, Low-dose--side effects; Oral Contraceptives--side effects; Research Methodology; Signs And Symptoms; Studies; United Kingdom; Use-effectiveness; Western Europe

Mesh:

Substances:

Year:  1979        PMID: 373792     DOI: 10.1111/j.1471-0528.1979.tb11263.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  3 in total

1.  Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg.

Authors:  D Cibula; U Karck; H G Weidenhammer; J Kunz; S Alincic; J Marr
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

2.  Oral contraceptive estrogen content and adverse effects.

Authors:  M Russell; S Ramcharan
Journal:  Can Fam Physician       Date:  1987-02       Impact factor: 3.275

Review 3.  20 µg versus >20 µg estrogen combined oral contraceptives for contraception.

Authors:  Maria F Gallo; Kavita Nanda; David A Grimes; Laureen M Lopez; Kenneth F Schulz
Journal:  Cochrane Database Syst Rev       Date:  2013-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.